Form 4: Maze Therapeutics Director Granted Stock Options

Maze Therapeutics director Jonathan E. Lim was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Summary

• Jonathan E. Lim, a Director at Maze Therapeutics, Inc. (MAZE), was granted 18,000 stock options.
• The options have an exercise price of $23.67 per share.
• The options will vest as to 1/9 of the total award monthly, with the first tranche vesting on October 1, 2025.
• Vesting is contingent upon Mr. Lim's continued service to the Issuer.
• The options have an expiration date of September 21, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director indicates continued alignment of management interests with shareholder value creation, a common practice in executive compensation.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term value creation.

Future Outlook

The stock options are subject to a monthly vesting schedule, with the first tranche vesting on October 1, 2025, provided the reporting person continues their service to the company.

Industry Context

NA

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders through increased focus on long-term value.
• Director (Jonathan E. Lim): Receives equity compensation, providing a direct financial stake in the company's future success.

Next Steps

• Continued service by Jonathan E. Lim to Maze Therapeutics for the options to vest according to the monthly schedule.

Key Dates

Recommendation

The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholder value. While positive for insider alignment, it does not provide new fundamental information to alter a broader investment thesis, thus a 'hold' recommendation is appropriate for existing positions.

Keywords

Maze Therapeutics, MAZE, stock option, insider transaction, director compensation, equity grant, beneficial ownership